LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly , which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR5 . It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR2/3 -selective LY-341,495 .[1] [2]
References [ edit ]
^ Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. Journal of Medicinal Chemistry . 1998 Jan 29;41(3):358-78. PMID 9464367
^ Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. British Journal of Pharmacology . 2000 Sep;131(2):239-44. PMID 10991916
Receptor
(ligands )
AMPA
NMDA
Antagonists: Competitive antagonists: AP5 (APV)
AP7
CGP-37849
CGP-39551
CGP-39653
CGP-40116
CGS-19755
CPP
LY-233,053
LY-235,959
LY-274,614
MDL-100,453
Midafotel (d-CPPene)
NPC-12,626
NPC-17,742
PBPD
PEAQX
Perzinfotel
PPDA
SDZ-220581
Selfotel ; Noncompetitive antagonists: ARR-15,896
Caroverine
Dexanabinol
FPL-12495
FR-115,427
Hodgkinsine
Magnesium
MDL-27,266
NPS-1506
Psychotridine
Zinc ; Uncompetitive pore blockers: 2-MDP
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
8A-PDHQ
18-MC
α-Endopsychosin
Alaproclate
Amantadine
Aptiganel
Arketamine
ARL-12,495
ARL-15,896-AR
ARL-16,247
Budipine
Conaridine
Delucemine
Dexoxadrol
Dextrallorphan
Dieticyclidine
Diphenidine
Dizocilpine
Ephenidine
Esketamine
Etoxadrol
Eticyclidine
Fluorolintane
Gacyclidine
Ibogaine
Ibogamine
Indantadol
Ketamine
Ketobemidone
Lanicemine
Loperamide
Memantine
Methadone (Levomethadone )
Methorphan (Dextromethorphan
Levomethorphan )
Methoxetamine
Methoxphenidine
Milnacipran
Morphanol (Dextrorphan
Levorphanol )
NEFA
Neramexane
Nitromemantine
Nitrous oxide
Noribogaine
Norketamine
Orphenadrine
PCPr
Pethidine (meperidine)
Phencyclamine
Phencyclidine
Propoxyphene
Remacemide
Rhynchophylline
Rimantadine
Rolicyclidine
Sabeluzole
Tabernanthine
Tenocyclidine
Tiletamine
Tramadol
Xenon ; Glycine site antagonists: 4-Cl-KYN (AV-101)
5,7-DCKA
7-CKA
ACC
ACEA-1011
ACEA-1328
AV-101
Carisoprodol
CGP-39653
CNQX
DNQX
Felbamate
Gavestinel
GV-196,771
Kynurenic acid
Kynurenine
L-689,560
L-701,324
Licostinel (ACEA-1021)
LU-73,068
MDL-105,519
Meprobamate
MRZ 2/576
PNQX
ZD-9379 ; NR2B subunit antagonists: Besonprodil
CERC-301 (MK-0657)
CO-101,244 (PD-174,494)
Eliprodil
Haloperidol
Ifenprodil
Isoxsuprine
Nylidrin
Ro8-4304
Ro25-6981
Traxoprodil ; Polyamine site antagonists: Arcaine
Co 101676
Diaminopropane
Diethylenetriamine
Huperzine A
Putrescine
Ro 25-6981 ; Unclassified/unsorted antagonists: Bumetanide
Chloroform
Cyclopropane
D -αAA
Diethyl ether
Enflurane
Ethanol
Flufenamic acid
Flupirtine
Furosemide
Halothane
Isoflurane
Metaphit
Methoxyflurane
Niflumic acid
Pentamidine isethionate
Piretanide
Toluene
Transcrocetin (saffron )
Trichloroethane
Trichloroethanol
Trichloroethylene
Xylene
Kainate
mGlu1
mGlu2
mGlu3
mGlu4
mGlu5
mGlu6
mGlu7
mGlu8
Transporter
(blockers )
Enzyme
(inhibitors )
Others